CARsgen Therapeutics Holdings Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Zonghai Li

Algemeen directeur

CN¥2.1m

Totale compensatie

Percentage CEO-salaris	50.2%
Dienstverband CEO	3.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Zonghai Li's beloning veranderd ten opzichte van CARsgen Therapeutics Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥695m
Mar 31 2024	n/a	n/a	-CN¥721m
Dec 31 2023	CN¥2m	CN¥1m	-CN¥748m
Sep 30 2023	n/a	n/a	-CN¥834m
Jun 30 2023	n/a	n/a	-CN¥920m
Mar 31 2023	n/a	n/a	-CN¥906m
Dec 31 2022	CN¥2m	CN¥1m	-CN¥892m

Compensatie versus markt: De totale vergoeding ($USD 287.63K ) Zonghai } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 392.73K ).

Compensatie versus inkomsten: De vergoeding van Zonghai is gestegen terwijl het bedrijf verliesgevend is.

CEO

Zonghai Li (50 yo)

3.8yrs

Tenure

CN¥2,084,000

Compensatie

Dr. Zonghai Li M.D., Ph D., is Co-Founder of CARsgen Therapeutics Holdings Limited and serves as its Chief Executive Officer and Chief Scientific Officer since February 2021 & Chairman of the Board. He ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Zonghai Li	Co-Founder	3.8yrs	CN¥2.08m	geen gegevens
Huamao Wang	Co-Founder	3.8yrs	CN¥2.11m	geen gegevens
Hua Jiang	Executive Director	2.3yrs	CN¥1.39m	geen gegevens
Hong Ma	Senior Vice President of Clinical Development	no data	geen gegevens	geen gegevens
Leigh Hsu	Senior Vice President of Business Development	no data	geen gegevens	geen gegevens
Raffaele Baffa	Chief Medical Officer	2.6yrs	geen gegevens	geen gegevens
Sylvie Peltier	Senior Vice President of Global Regulatory Affairs	2.1yrs	geen gegevens	geen gegevens
Wing Yat Lui	Company Secretary	3.8yrs	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2171 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Zonghai Li	Co-Founder	6.8yrs	CN¥2.08m	geen gegevens
Huamao Wang	Co-Founder	6.2yrs	CN¥2.11m	geen gegevens
Hua Jiang	Executive Director	2.3yrs	CN¥1.39m	geen gegevens
Ronggang Xie	Non-Executive Director	4.2yrs	geen gegevens	geen gegevens
Xiangke Zhao	Independent Non-Executive Director	1.3yrs	CN¥80.00k	geen gegevens
Bingsen Guo	Non-Executive Director	6.2yrs	geen gegevens	1.62% HK$ 62.4m
Guangmei Yan	Independent Non-Executive Director	3.4yrs	CN¥222.00k	geen gegevens
Huaqing Guo	Non-Executive Director	4.2yrs	geen gegevens	0.38% HK$ 14.6m
Wen Zhou	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2171 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

CARsgen Therapeutics Holdings Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Non-Executive Director recently bought HK$903k worth of stock

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Recent updates

New major risk - Share price stability

CARsgen Therapeutics Holdings Limited Announces That the U.S. Food and Drug Administration (FDA) Loses the Clinical Holds on Clinical Trials of Zevor-Ccel

Carsgen Therapeutics Holdings Limited Submits Application to Request Lifting Clinical Holds to FDA

CARsgen Therapeutics Holdings Limited Announces Completion of Enrollment of Confirmatory Phase II Clinical Trial of Satricabtagene Autoleucel in China

CARsgen Therapeutics Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Share price stability

Non-Executive Director recently bought HK$903k worth of stock

Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New major risk - Share price stability

Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug (IND) Clearance from the National Medical Products Administration

CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting

CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting

CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival

CARsgen Therapeutics Holdings Limited to Report First Half, 2023 Results on Aug 22, 2023

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041

CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer

CARsgen Therapeutics Holdings Limited Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Insider recently sold HK$14m worth of stock

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited Appoints Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Holdings Limited Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

Carsgen Therapeutics Holdings Limited Releases First Clinical Batch from the RTP GMP Manufacturing Facility in North Carolina

CARsgen Therapeutics Holdings Limited Announces Case Report of Long Term Complete Response in Hepatocellular Carcinoma to It's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Therapeutics Holdings Limited to Report First Half, 2022 Results on Aug 23, 2022

CARsgen Therapeutics Holdings Limited Announces Appointment of Dr. Hua JIANG as Executive Director

CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Insider recently sold HK$8.8m worth of stock

Insider recently sold HK$14m worth of stock

Insider recently sold HK$1.9m worth of stock

Insider recently sold HK$10m worth of stock

Carsgen TheCARsgen Therapeutics Holdings Limited Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

CARsgen Therapeutics Holdings Limited Announces Resignation of Zhao Yachao as Non-Executive Director

Insider recently sold HK$3.0m worth of stock

CARsgen Therapeutics Holdings Limited Announces Results of the Investigator-Initiated Trial of CT041 Were Reported in the Nature Medicine

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 25, 2022

Carsgen Therapeutics Holdings Limited Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Therapeutics Holdings Limited Announces Approval from Center for Drug Evaluation of National Medical Products Administration of China for the Initiation of the CT041 Confirmatory Phase II Clinical Trial

CARsgen Therapeutics Holdings Limited Announces United States Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to CT041

CARsgen Therapeutics Holdings Limited Announces Clinical Trial Application for Ct041 Authorised by Health Canada

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd